Search results
Showing 1231 to 1245 of 1433 results for primary care
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .
practice was unclear because of subsequent improvements in perioperative care such as better preoperative risk assessment and...
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued Reference number: GID-TA10065
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued Reference number: GID-TAG393
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070
Evidence-based recommendations on enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable.
Compression products for treating venous leg ulcers: late-stage assessment (HTG758)
Late-stage assessment (LSA) guidance on compression products for treating venous leg ulcers.
View recommendations for HTG758Show all sections
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.